Miltefosine is an alkyllysophospholipid analogue drug with in vitro activity against the promastigote and amastigote stages of Leishmania species. It is already approved to treat visceral, mucosal and cutaneous leishmaniasis in patients aged ≥12 years; it is the first oral treatment for this rare tropical parasitic disease.
"Less than 1% with the infection are receiving treatment for Chagas disease," said Dr. Sheba Meymandi, Director of the Center of Excellence for Chagas Disease at Olive View-UCLA Medical Center.
Profounda announced that the Food and Drug Administration (FDA) has granted Orphan Drug Designation for Impavido (miltefosine) to treat primary amebic meningoencephalitis (PAM), also known as the "Brain Eating Amoeba".
Profounda announced the launch of Impavido (miltefosine) for the treatment of visceral, mucosal, and cutaneous leishmaniasis in patients aged ≥12 years.
Imprimis Pharmaceuticals announced that it has made available a compounded formulation of pyrimethamine and leucovorin as a lower-cost alternative to Daraprim (pyrimethamine; Turing Pharmaceuticals).
Turing Pharmaceuticals has agreed to reduce the cost of its drug Daraprim (pyrimethamine) after receiving significant criticism due to a sudden increase in the price of the medication.
Clinicians should exercise caution when prescribing steroids in patients presenting with an exacerbation of asthma in areas endemic for Strongyloides stercoralis (SS), as a patient experienced hyperinfection syndrome from prednisone treatment at the time of SS infection.
New policy guidelines issued by the White House Office of Science and Technology Policy are calling for U.S. universities to carefully monitor their life sciences research on dangerous pathogens and toxins for both benefits and risks.
Guidance is provided for screening adolescents and young adults for sexually transmitted infections (STIs) in an American Association of Pediatrics (AAP) Policy Statement.
Compared to the standard of care (benznidazole), the new drug posaconazole is not effective for the treatment of Chagas' disease.
The Centers for Disease Control (CDC) has targeted 5 neglected parasitic infections (NPIs) in the United States as priorities for public health action.
The FDA has approved Impavido (miltefosine; Paladin Therapeutics) for the treatment of three main types of leishmaniasis: visceral, cutaneous, and mucosal leishmaniasis in patients ≥12 years of age.
Solid organ transplant recipients who become febrile weeks after transplantation may have acquired microsporidiosis from Encephalitozoon cuniculi.
The investigational drug miltefosine is now available from the CDC for patients with infections caused by free-living amebae (FLA).
As of August 1, 2013, the CDC has been notified of 400 cases of Cyclospora infection from 15 health departments.
Cases of the intestinal infection, cyclosporiasis have caught the U.S. Centers of Disease Control and Prevention's attention when in June individuals who had not been traveling internationally at the time were infected.
Adults and children with intraparenchymal neurocysticercosis, a tapeworm infection causing seizures most commonly in developing countries of Africa, Asia, and Latin America, should be treated with albendazole plus either dexamethasone or prednisolone.
Luminex announced that it has received FDA clearance for its xTAG Gastrointestinal Pathogen Panel (GPP), a comprehensive molecular diagnostic assay that tests for >90% of bacterial, viral, and parasitic causes of infectious gastroenteritis in a single assay.
Two patients who died of an amebic infection had no history of freshwater exposure but had ameba in their household plumbing and used a nasal irrigation device for sinus problems.
Women infected with the common parasite Toxoplasma gondii (T. gondii) have an increased risk of self-directed violence, violent suicide attempts, and suicide.
The FDA has notified healthcare professionals not to use the intravenous medications, metronidazole, ciprofloxacin and ondansetron manufactured by Claris Lifesciences due to contamination.